Adcetris (brentuximab vedotin) / Takeda, Pfizer - LARVOL DELTA

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma (ASH 2025) - "Introduction:Brentuximab vedotin (BV) and nivolumab (N) have resulted in significant progress in the treatment ofadvanced-stage Hodgkin lymphoma (AS-HL). The SWOG 1826 trial demonstrated a progression-freesurvival (PFS) and safety benefit with frontline N-AVD (doxorubicin, vinblastine, and dacarbazine)compared to BV-AVD; however, real-world data are limited...This large real-world multicenter study demonstrates that response rates and 1-yr survival outcomes withN-AVD and BV-AVD are similar to the published SWOG 1826 trial (N-AVD vs BV-AVD: 1-yr PFS: 94% vs 86%,Herrera et al. 2024). Increased cardiovascular AEs, dose reductions/omissions and neuropathy with BV-AVD indicate better tolerability with N-AVD; however, the higher rate of febrile neutropenia andinfections in comparison to SWOG 1826 in N-AVD pts suggests that growth factor prophylaxis may bebeneficial in select high-risk subgroups."

Clinical • Clinical data • Combination therapy • Metastases • Real-world • Real-world evidence • Cardiovascular • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Pediatrics • Septic Shock • Thrombosis

Respiratory Disorders Associated with Antibody-Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases. (PubMed, Clin Pharmacol Ther) - "The disproportionality analysis showed a significant signal for interstitial lung disease with brentuximab vedotin, polatuzumab vedotin, trastuzumab emtansine, and trastuzumab deruxtecan...All antibody-drug conjugates, except belantamab mafodotin and enfortumab vedotin, were associated with a significant signal for pleural disorders. Our study highlights the risk of interstitial lung disease with these drugs in real-world settings and identified pulmonary arterial hypertension and pleural disorders as additional safety signals. Further research is needed to confirm these findings in population-based studies and to identify antibody-drug conjugates and patient-related risk factors."

Adverse events • Journal • Breast Cancer • Cardiovascular • Hypertension • Interstitial Lung Disease • Oncology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Solid Tumor

Access to diagnostics, therapies, and advanced care for lymphoma in Latin America: A multicenter, survey-based study (ASH 2025) - "Regarding drug access,partial or restricted access to rituximab was reported in 27 centers (35.8%)...Access to advanced therapies was reported as highly restricted:brentuximab vedotin (n=16, 31%), polatuzumab vedotin (n=37, 65%), tafasitamab (n=12, 80%), glofitamab(n=16, 73%), epcoritamab (n=19, 72.7%)... Our findings highlight striking disparities in access to diagnostics, treatments, and advancedtherapeutic modalities across Latin America. CAR-T therapy, transplant capabilities, and access to noveldrugs remain highly restricted and unevenly distributed. Additionally, most centers lack participation inclinical trials."

Clinical • IO biomarker • Metastases • Hematological Malignancies • Lymphoma

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers. (PubMed, Eur J Haematol) - P | "BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. In Ya&A with high-risk cHL, our data suggest that a BV-driven strategy (without bleomycin and consolidation radiotherapy) is an effective up-front option in oncologic centers specialized in HL care, improving the rate of durable complete remission in routine clinical practice. Trial Registration: ClinicalTrials.gov identifier: NCT06857500."

Journal • Cardiovascular • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain

Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis (ASH 2025) - P | "Of these, 14 (52%) received axi-cel, 11 (40%)tisa-cel, and 2 (7%) liso-cel...Salvage treatments included checkpointinhibitors (CPI, pembrolizumab or nivolumab) in 11 pts, with four of them received also brentuximab-vedotin; chemotherapy in 1 patient (Rituximab-bendamustine + polatuzumab-vedotin); anti-CD3/CD20bispecific antibodies in 6 pts (glofitamab, epcoritamab or plamotamab); and various others therapy in 4pts... This study outlines the treatment features and outcomes of pts with PMBL who relapseafter CAR-T cell therapy and highlights the potential of CPIs as a preferred treatment option followingCAR-T cell failure. Given the young age of most pts and the frequent off-label use of CPIs across manycountries, these findings emphasize the importance of a structured, multidisciplinary expert approach tosupport timely and individualized management decisions in this rare but potentially curable population."

CAR T-Cell Therapy • Clinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis (ASH 2025) - "In patients that proceeded to ASCT, relapses occurred in 10pts (40%) with a 3 yr PFS and OS 56% and 83%, respectively.CAR-T was used as 2L in 20 pts (14%)- most commonly either axi-cel (N =7) or liso-cel (N = 8)...Other 2L treatments included pembrolizumab (N =3), brentuximabvedotin (BV) + nivolumab (N= 4) or single agent BV (N=2)... We report the largest cohort of pts with RR PMBCL treated in the rituximab era and thelargest number of PMBCL pts treated with 2L CAR-T. This is the first analysis, to our knowledge, to show astatistically significant benefit in PFS, ORR and CR rate of CAR-T compared to platinum salvage followedby HDT/ASCT as 2L treatment in a study of exclusively RR PMBCL pts. Our dataset was largely (93%)compromised of pts with primary refractory or early relapsing disease and provides support for usingCAR-T as 2L treatment in this high-risk subset of RR PMBCL patients."

Retrospective data • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

Targeted therapies and resistance mechanisms in lymphoma: Current landscape and emerging solutions. (PubMed, Oncoscience) - "We comprehensively evaluate FDA-approved targeted agents, including monoclonal antibodies (rituximab, brentuximab vedotin, obinutuzumab, mogamulizumab), immune checkpoint inhibitors (nivolumab, pembrolizumab), CAR T-cell therapies (axi-cel, tisa-cel, liso-cel, brexu-cel), bispecific T-cell engagers (mosunetuzumab, epcoritamab), and small-molecule inhibitors (ibrutinib, idelalisib, venetoclax). In conclusion, understanding the molecular basis of lymphoma and resistance mechanisms is critical to optimizing targeted therapy. This review synthesizes current evidence to inform clinical decision-making and outlines future directions for durable, personalized lymphoma care."

IO biomarker • Journal • Review • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BTK • CCR4 • CD20 • TNFRSF8

Immune mediated inflammatory disease: T cell engager versus antibody drug conjugate. (PubMed, J Autoimmun) - "In contrast, ADCs deliver immunomodulatory payloads to disease-relevant cells, with agents like ABBV-154 and brentuximab vedotin showing promise in rheumatoid arthritis and systemic sclerosis. However, challenges such as cytokine release syndrome with TCEs and off- and on-target toxicities with ADCs highlight the need for optimal target selection and innovative design. This review provides a comprehensive comparison of the mechanisms, current evidence, and future directions of TCEs and ADCs in IMIDs, highlighting their potential to address unmet needs in disease management."

Journal • Review • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis

ALK Inhibition as an Effective Salvage Strategy in a Patient with primary Refractory ALK+ ALCL (DGHO 2025) - "ALK+ ALCL is typically chemotherapy-responsive and treated with immunochemotherapy consisted of brentuximab-vedotin with cyclophosphamide, doxorubicine and prednisone (BV-CHP)...HLH was refractory to single treatment of 100mg/qm etoposide. Given the data on ALK inhibitors in pediatric patients with R/R ALK+ ALCL, we decided to introduce the ALK inhibitor crizotinib (CZ) as "off-label" salvage therapy instead of conventional chemotherapy. CZ was given at a dose of 250mg twice a day, resulting in dramatic clinical improvement within 48 hours, immediate resolution of HLH and complete radiological response with MRD-negativity in peripheral blood 6 weeks after initiation of CZ...Treatment was switched to lorlatinib to account for the risk of CNS relapse four weeks after introducing ALK Inhibitor therapy... This case strongly supports ALK-inhibitors as a very effective salvage therapy option in R/R ALK+ ALCL, achieving MRD negative CR and enabling allo-SCT...."

Clinical • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Pediatrics • T Cell Non-Hodgkin Lymphoma • TNFRSF8

"A case of aggressive mediastinal gray zone lymphoma: Don't give up!" (DGHO 2025) - "The biopsy was consistent with MGZL, immunophenotype CD20 pos, CD30 pos, CD15 neg. We started the patient on prephase prednisolone and one cycle of R-CHOP for prevention of tumor lysis followed from 5 cycles of DA-EPOCH-R...A bridging therapy with brentuximab vedotin was initiated and an application for reimbursement of CAR-Ts was submitted. The CAR-Ts (Anti-CD19, Breyanzi) were administered after approval on November 4, 2024...We conclude that in primary refractory MGZL, immune and cellular therapy should be considered earlier. [GL1]"

Clinical • B Cell Lymphoma • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Respiratory Diseases • CD20 • TNFRSF8

Experience with VECADD In Advanced classic Hodgkin Lymphoma In Pregnant And Non-pregnant Female Patients: A Case Series (DGHO 2025) - "BrECADD (Brentuximab vedotin (BV), etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) has proven high efficacy and favorable tolerability for advanced-stage cHL (AS-cHL); however, the use of BV during pregnancy is prohibited...3 pregnant and all non-pregnant women received (peg-)filgrastim during VECADD...3 also received VECADD after birth, 2 received ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and 1 received eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)... We did not observe any impact of VECADD on the pregnancy, fetus, delivery or child at birth in pregnant patients. Tolerability is good for both groups.VECADD was effective with all patients achieving a durable CR so far. Our observations with VECADD during pregnancy support the approach of intensified therapy with a curative intention in pregnant patients with cHL."

Clinical • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma

Hodgkin lymphoma associated hemophagocytic lymphohistiocytosis resistant to dexamethasone and etoposide successfully treated with brentuximab vedotin monotherapy (DGHO 2025) - "Subsequently, the therapy was extended by doxorubicin and dacarbazine (without vinblastine due to PNP). In adults, lymphoma is the most common cause of secondary HLH. Hence, in patients presenting with fever, hepatosplenomegaly, cytopenia, strongly elevated ferritin and sIL2R levels, an intensive diagnostic work-up should be pursued to enable targeted therapy of the underlying malignancy. Even in cases of severe liver and kidney failure, BV represents a safe and highly effective therapeutic option for HL-associated HLH."

Monotherapy • CNS Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hepatic Encephalopathy • Hepatology • Hodgkin Lymphoma • Immunology • Infectious Disease • Liver Failure • Lymphoma • Nephrology • Rare Diseases • Renal Disease • Septic Shock • IL2

PD-1-based Salvage Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Multicenter Real-World Analysis (DGHO 2025) - "For example, P-GVD (pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin) achieved CR rates of up to 95% with unprecedented PFS after HD-ASCT (Moskowitz et al., JCO 2021)...Salvage regimens were PD-1 monotherapy (pembrolizumab/nivolumab), PD-1 + chemotherapy [pembrolizumab or nivolumab + ifosfamide, carboplatin, and etoposide (N- ICE/ P-ICE) or P-GVD], or PD-1 + BV (brentuximab vedotin).Overall response rate (ORR) was 92.5%, with 47.5% achieving CR, 45% partial response (PR), and 7.5% stable disease (SD) (40 evaluable pts.)... Our findings provide real-world evidence on PD-1–based salvage in European centers. While previously reported high CR rates were not reached, outcomes after HD-ASCT were excellent, supporting the role of PD-1 inhibitors in salvage therapy followed by consolidation for r/r cHL."

Clinical • Real-world • Real-world evidence • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

HX111, A FIC OX40-mAb-VC-MMAE ADC for the treatment of lymphoma (SITC 2025) - "It was also tested several lymphoma-CDX and -PDXs for their anti-lymphoma pharmacology.Results VC-MMAE was chosen as the linker-payload of HX111 for its proven efficient killing of lymphoma cells, as shown by Adcetris. In addition, we also observed enhanced anti-lymphoma effects when HX111 combined with an immune checkpoint inhibitor, HX009,1 2 a BsAb of PD-1 x SIRPα in the LY6698 B-lymphoma PDX.Conclusions The lymphoma-associated OX40-expression can be explored for the treatment of OX40+ T-cell or B-cell lymphomas, both being unmet medical needs, and HX111 could potentially be such a candidate treatment, warranting further clinical investigation.Ethics Approval All animal studies were conducted at SPF facility in strict accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the IACUC Committee."

IO biomarker • Adult T-Cell Leukemia-Lymphoma • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • T Cell Non-Hodgkin Lymphoma • SIRPA • TNFRSF4 • TNFSF4

Differential prognostic impact of chromatin modifier mutations in peripheral T-cell lymphoma: KMT2A emerges as a critical biomarker (ASH 2025) - "Ten patients got brentuximab vedotin as part of their initial treatment, butthis didn't improve outcomes compared to standard CHOP chemotherapy... Our study reveals that KMT2A mutations occur in about a quarter of Asian PTCL patientsand predict significantly worse outcomes. This finding, along with the poor prognosis associated withDNMT3A mutations, suggests these genetic alterations could help identify patients who need moreaggressive or experimental treatments upfront. The fact that TET2 mutations didn't affect survival,despite being frequently studied in PTCL, shows that not all epigenetic mutations are equal."

Biomarker • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ATR • DNMT3A • KMT2A • SETD2 • TET2 • TP53

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China (ASH 2025) - "Adverse drug reactions (ADRs) were observed in 39.3%, and no ADR-relatedmortality occurred.In ND pts, the median dose intensity was 1.67 (IQR: 1.39-1.85) mg/kg with a median dose of 4.5 (IQR: 3.0-6.0) cycles, and the majority of pts (58.7%) received the BV-R (Rituximab) -CHP (Cyclophosphamide,Doxorubicin and Prednisone) regimen. The real-world BRAVE study demonstrated that BV was well tolerated and showedpromising effectiveness in Chinese patients with ND and R/R BCL regardless of the CD30 expressionstatus. These findings suggest the potential of broader clinical applicability of BV in BCL management."

Clinical • Observational data • Real-world • Real-world evidence • B Cell Lymphoma • Classical Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hodgkin Lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Systemic Anaplastic Large Cell Lymphoma • TNFRSF8

Peripheral T-cell lymphomas: Real-world insights into clinical features and prognosis (ASH 2025) - "According to PIT, 27.2% had low risk, 26.2% low-intermediate, 27.2%high-intermediate, and 19.4% high risk.Regarding first-line treatment, 75% received anthracycline-based regimens, 7% brentuximab-based, and18% did not receive systemic therapy due to severe clinical conditions...This study provides one of the largest single-center descriptions of PTCL in Mexico and Latin America,highlighting advanced-stage disease at diagnosis, a third of R/R cases, and the limited access to targetedtherapies and HSCT. Response rates and survival outcomes remain poor, particularly for PTCL-NOS andAITL. These findings underscore the urgent need for improved diagnostic and therapeutic access, andrisk-adapted therapies to improve survival in this vulnerable population."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • B2M • CD5

Brentuximab vedotin plus DHAP as effective salvage therapy in CD30+ peripheral T-cell lymphoma: A retrospective multicenter study (ASH 2025) - "Recently, forthe first time, a significant OS benefit was demonstrated for the combination of brentuximab vedotin (BV)and CHP (cyclophosphamide, doxorubicin, prednisone) compared to CHOP (cyclophosphamide,doxorubicin, vincristine, prednisone) in the first-line treatment of patients with anaplastic large celllymphoma (ALCL)...In Hodgkin lymphoma, the addition of BVto DHAP (dexamethasone, high-dose cytarabine, cisplatin) has shown promising efficacy as a salvageregimen in a phase II trial...No new cases of peripheral neuropathy weredocumented.In conclusion, BV-DHAP was particularly effective as a salvage regimen in this high-risk cohort of R/RCD30-positive T-cell non-Hodgkin lymphoma, with manageable toxicity. Further studies are warranted toestablish its superiority over BV monotherapy in this setting."

Retrospective data • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis (ASH 2025) - "However,advances have been made since then in developing targeted therapies including brentuximab-vedotin,HDAC, PI3K, EZH, and JAK inhibitors and others, and more frequent use of alloHCT... We analyzed a large cohort of pts with R/R PTCL initiating 2L systemic therapy in an era withadditional treatment options and increasing use of novel therapies. Since prior publications, we highlightimproved OS, suggesting that recent therapeutic advances are improving longer-term outcomes. MedPFSto 2L appeared similar to prior series, suggesting that recent expansion of treatment options has allowedfor more opportunities to identify an effective therapy for an individual patient."

Retrospective data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Persistent racial disparities in Sézary syndrome outcomes despite use of modern therapies: A single-center analysis (ASH 2025) - "With theincreasing use of modern systemic therapies (e.g., mogamulizumab, brentuximab vedotin, interferons,photopheresis) over the past decade, we sought to determine whether survival disparities by race persistin the current treatment era.MethodsWe retrospectively reviewed 75 patients with SS treated between January 2015 and June 2025 at MoffittCancer Center...Black patients were more likely toreceive ECP + Pegasys (69.2% vs. 26.8%), romidepsin (61.5% vs. 37.5%), brentuximab (38.5% vs. 14.3%),and combination chemotherapy (61.5% vs. 19.6%) compared to White patients, likely reflecting the moreaggressive nature of their disease.ConclusionOur cohort demonstrated better OS compared to historical studies, likely reflecting the impact of modernsystemic therapies and specialized care at a tertiary center...Black patients in our cohort had a markedly higher prevalence of large-celltransformation, earlier age at diagnosis, and more advanced clinical stage at presentation,..."

Clinical • Cutaneous T-cell Lymphoma • Dermatopathology • Hematological Malignancies • Lymphoma • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study (ASH 2025) - P2 | "Current monotherapies yieldonly modest overall response rates (ORR) ranging from 22% to 38%, except for brentuximab vedotin inCD30-positive anaplastic large cell lymphoma (ALCL). The most common grade ≥3 treatment-related adverse eventsincluded neutropenia (83.3%), thrombocytopenia (75.0%), leukocytopenia (50.0%), lymphocytopenia(41.7%), anemia (20.8%), infectious pneumonia (16.7%), bacterial pneumonia (12.5%), and hypokalemia(12.5%). There was one treatment-related death due to infection.ConclusionPreliminary results from this phase IIa study indicate that PM administered in 21-day cycles demonstratespromising efficacy compared with currently available single agents, with a manageable safety profile inpatients with R/R PTCL."

P2a data • Anemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Pneumonia • Respiratory Diseases • Systemic Anaplastic Large Cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia

Targeted immunotherapy in children, adolescents, and young adults (CAYA) with newly diagnosed classical Hodgkin lymphoma: A single center experience (ASH 2025) - "Ourapproach combines the use of the antibody-drug conjugat,e brentuximab vedotin (Bv), targeting Reed-Sternberg (RS) cells, along with the anti-CD20 antibody rituximab (RTX) and checkpoint inhibitornivolumab (N) targeting the TME, added to risk-adapted chemotherapy in newly diagnosed CAYA cHLpatients. This chemoimmunotherapy approach allows for anthracycline dose reduction and radiationsparing in intermediate and high-risk patients.Our early cHL clinical trial enrolled patients 3-39yr old who received a backbone of brentuximab vedotin,doxorubicin, vinblastine, dacarbazine, and rituximab (Bv-AVD-R) given on Day 1, 2 and Day 15,16 of eachcycle...The addition of immunotherapy to a reduced-intensity chemotherapy backbone is safe, effective and welltolerated. Targeting the HRS cell as well as the TME via the PD1/PD-L1 axis is a promising approach inCAYA with cHL and allows for reduction in both anthracycline and radiation exposure. This is important inlimiting short- and..."

Clinical • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hodgkin Lymphoma • Lymphoma • Mucositis • Neutropenia • Pediatrics

Brentuximab vedotin (Bv)+AVD efficacy is influenced by interim PET, age, ECOG performance status and CIRS-g in previously untreated patients with stage IV classical Hodgkin lymphoma: An Italian real-life multicentric study (ASH 2025) - "Introduction: In Italy, Brentuximab vedotin (Bv) with AVD (adriamycin, vinblastine, dacarbazine) receivedapproval for the first-line treatment of stage IV classical Hodgkin lymphoma (cHL) in September 2021,with no upper age restriction. In a real-life population of stage IV adult cHL, the Bv+AVD regimen efficacy on PFS isinfluenced by TTM, interim PET DS4-5 (that also impacted on OS), age, ECOG-PS and CIRS-G. The Frailtyscore appears useful to select who can benefit less from Bv-AVD and could represent a tool to betterstratify patients in the era of novel standards for the first-line therapy of advanced stage cHL."

Clinical • Metastases • Classical Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Neutropenia

Comparable survival with transplant-free approach versus autologous stem cell transplantation in adult relapsed/refractory classic Hodgkin lymphoma achieving complete remission (ASH 2025) - "Recentphase II trials (Daw et al., 2025a, b; Hoppe et al., 2025) have demonstrated that low-risk pediatric andyoung adult patients achieving CR with nivolumab-brentuximab vedotin plus radiotherapy, or withconventional regimens, can achieve 5-year event-free survival (EFS) rates exceeding 80% withoutHDT/ASCT, thereby avoiding the significantly increased late mortality associated with transplantation(Buhtoiarov & Hanna, 2025). In the HDT/ASCT group, salvage therapiesincluded CPI-based (n=16), BV-based (n=1) and chemotherapy-based (n=30) regimens, with 28 patientsreceiving post-transplant maintenance therapy (PD-1 inhibitors [n=22], thalidomide/lenalidomide [n=5],or BV [n=1]).With a median follow-up of 3.6 years (IQR, 2.2-5.7) after salvage initiation, 50 patients experienceddisease progression: 36 patients (31.0%) in the transplant-free group and 14 patients (29.8%) in theHDT/ASCT group. The 3-year PFS was 68.3% in the transplant-free group and 74.0% in the..."

Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Pediatrics • Transplantation

Nivolumab and pembrolizumab in treatment of relapsed or refractory classical Hodgkin lymphoma: Systematic review and meta-analysis of clinical trials (ASH 2025) - "Managementinvolves platinum/gemcitabine-based chemotherapy, brentuximab vedotin (BV), autologous stem celltransplant (ASCT), or PD-1 inhibitors that have led to improved outcomes in the past decade...Nivolumab andpembrolizumab monotherapies were investigated in 5 and 3 trials, respectively; BV with nivolumab wasstudied in 2 trials, the rest of the studies evaluated different combinations of immune-chemotherapies(n=2) or different immunotherapies (n=4), such as ipilimumab (±BV) and lirilumab... This meta-analysis confirms that both pembrolizumab and nivolumab in the treatment ofr/r cHL similarly improve clinical outcomes with an acceptable safety profile. As the treatment landscapeof r/r cHL evolves and with the introduction of PD-1 inhibitors in the frontline setting, the efficacy of theseagents in combination with other treatment modalities, including emerging immunotherapeutic agents,should be investigated. Patients with multiple comorbidities, prior..."

Retrospective data • Review • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Human Immunodeficiency Virus • Infectious Disease • Lymphoma